Abstract：
The landscape of severe dyslipidemia treatment is undergoing a remarkable transformation with the advent of angiopoietin-like 3 (ANGPTL3) inhibitors. ANGPTL3, a pivotal regulator of lipoprotein lipase and endothelial lipase, orchestrates the catabolism of triglyceride-rich and high-density lipoproteins, thus playing a critical role in lipid homeostasis. This review article examines the therapeutic potential of ANGPTL3 blockade and its implications for patients with severe dyslipidemias, particularly those unresponsive to traditional lipid-lowering regimens. We delve into the molecular mechanisms by which ANGPTL3 influences lipid metabolism and appraise the clinical utility of emerging therapeutics, such as monoclonal antibodies and antisense oligonucleotides. Moreover, we discuss the impact of ANGPTL3 inhibition on cardiovascular risk factors and project its promising role in reducing cardiovascular morbidity and mortality. The narrative synthesizes data from recent clinical trials, including the efficacy and safety profiles of ANGPTL3 inhibitors, and forecasts the potential of these agents to revolutionize the management of dyslipidemic conditions. The advent of ANGPTL3-targeted therapies signifies a potential breakthrough in the therapeutic armamentarium against complex lipid disorders, heralding a new era of precision medicine in cardiovascular risk mitigation.
摘要：
随着血管生成素样3（ANGPTL3）抑制剂的出现，严重的血脂异常治疗正在发生显着的变化。ANGPTL3是脂蛋白脂肪酶和内皮脂肪酶的关键调节因子,协调富含甘油三酯和高密度脂蛋白的分解代谢，因此在脂质稳态中起关键作用。这篇综述文章探讨了ANGPTL3阻断的治疗潜力及其对重度血脂异常患者的影响。特别是那些对传统降脂方案无反应的患者。我们深入研究了ANGPTL3影响脂质代谢的分子机制，并评估了新兴疗法的临床实用性，如单克隆抗体和反义寡核苷酸。此外，我们讨论了ANGPTL3抑制对心血管危险因素的影响,并预测其在降低心血管发病率和死亡率方面的有希望的作用.叙述综合了最近临床试验的数据，包括ANGPTL3抑制剂的疗效和安全性，并预测这些药物彻底改变血脂异常疾病管理的潜力。ANGPTL3靶向疗法的出现标志着针对复杂脂质紊乱的治疗性医疗设备的潜在突破，预示着精准医学在心血管风险缓解方面的新时代。
